Company Overview

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the prevention and treatment of breast cancer and other breast health conditions. The company operates within the biotechnology and pharmaceutical research and development industries, with a primary emphasis on oncology and endocrine-related diseases. Its business model centers on advancing proprietary drug candidates through clinical development rather than commercial product sales, and as a result, it has historically generated no recurring product revenue.

The company’s core strategic focus is on addressing unmet needs in breast cancer, particularly estrogen receptor–positive (ER+) breast cancer and conditions affecting women at high risk of developing the disease. Atossa was founded in 2008 and has evolved from earlier diagnostic-focused efforts into a therapeutics-driven organization. Over time, it has streamlined its pipeline to concentrate on endocrine-based drug candidates with differentiated mechanisms of action, positioning itself as a niche innovator in breast health therapeutics.

Business Operations

Atossa Therapeutics’ operations are organized around a single reportable operating segment focused on drug discovery and clinical development. The company’s primary assets include its proprietary drug candidates, most notably (Z)-endoxifen, an active metabolite of tamoxifen being studied for multiple breast cancer–related indications. Revenue generation is not currently derived from commercial products; instead, the company relies on capital raised through equity offerings to fund research, clinical trials, and general corporate operations.

The company conducts its clinical and regulatory activities primarily in the United States, leveraging third-party contract research organizations, manufacturers, and clinical trial sites rather than maintaining internal large-scale manufacturing or distribution capabilities. Atossa does not currently report material joint ventures or revenue-generating subsidiaries, and its operational structure is intentionally lean to support flexibility in early-stage clinical development.

Strategic Position & Investments

Atossa’s strategic direction is centered on advancing (Z)-endoxifen through clinical trials for both therapeutic and preventative breast cancer indications, including neoadjuvant and risk-reduction settings. The company aims to differentiate its pipeline by targeting patient populations that may not respond optimally to existing endocrine therapies, thereby potentially expanding the standard of care in ER+ breast cancer management.

Investment activity has primarily taken the form of internal research and development spending rather than large-scale acquisitions. Atossa has periodically acquired intellectual property rights and licenses related to its drug candidates to strengthen its portfolio. Its strategy emphasizes capital discipline, focused clinical milestones, and maintaining optionality for future partnerships or licensing arrangements if later-stage data support broader commercialization efforts.

Geographic Footprint

Atossa Therapeutics is headquartered in Seattle, Washington, and its operational footprint is primarily concentrated in the United States. Clinical trials and regulatory engagements are largely U.S.-based, reflecting the company’s focus on the U.S. Food and Drug Administration approval pathway and the North American oncology market.

While the company does not maintain significant physical operations outside the United States, its clinical research activities may involve international study sites depending on trial design and regulatory requirements. International exposure remains limited and primarily indirect, with no material foreign subsidiaries or manufacturing facilities reported in public disclosures.

Leadership & Governance

Atossa is led by an executive team with experience in biotechnology, clinical research, and corporate governance, with strategic oversight provided by its board of directors. Leadership emphasizes disciplined capital allocation, scientific rigor, and a focused approach to advancing a limited number of high-potential clinical assets.

• Steven C. Quay, M.D., Ph.D. – Chief Executive Officer, President, and Chairman of the Board
• Kyle Guse, CPA – Chief Financial Officer and Treasurer
• Michelle Shogren – General Counsel and Corporate Secretary
• Robert L. O’Connell, Ph.D. – Senior Vice President, Clinical and Regulatory Affairs

The company’s governance structure reflects its status as a publicly traded clinical-stage biotechnology firm, with leadership closely involved in both scientific strategy and capital markets execution.